Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

DepressiStim Announces Clinical Trial Progress

Mission Viejo, California, United States - 03-03-2023 (PR Distribution™) -

DepressiStim TM Reports Progress on Treatment Resistant Depression Pilot Clinical Study 

The DepressiStim TM Brain Band therapy system is intended to be indicated for adjunctive non-invasive treatment of chronic or recurrent depression in patients who are experiencing a recent depressive episode and whom do not have an adequate response to standard medications or therapies. 

March 3rd, 2023 - Porto Alegre, Brazil  and Mission Viejo, CA-  DepressiStim TM (a Leonhardt Ventures LLC Co.) enrolled the first cohort of patients in a pilot study that will evaluate the Brain Band TM for DepressiStim TM to treat depression with non-invasive bioelectric stimulation technology.  The pilot study received local institutional review board ethics committee approval. The device used has Anivisa clearance in Brazil and simultaneously the DepressiStim team is also working toward FDA clearance. The device uses low-intensity proprietary bioelectrical signaling sequencing programmed to control specific mood-related protein expressions on demand in brain tissue.  These specific signaling sequences are patented or patent pending by Leonhardt Ventures LLC and are exclusively licensed to DepressiStim LTP for treating depression. 

The objective of the pilot study is to determine whether the specific signaling sequence combined with the non-invasive bioelectric therapy treatment can safely and effectively reduce depressive symptom severity.  The non-randomized prospective pilot study for manic depression will include 10 patients. Treatment sessions are 40 minutes five times per week for three weeks, equating to 15 treatments total. Followup will be 3 months. All patients will be tested for changes in serotonin, klotho, brain derived neurotrophic factor (BDNF) and down regulation of TNFa in blood serum levels. Changes in depression symptoms are measured using Montgomery Asberg Depression Rating Scale.

The first patient enrolled that completed the full 3 weeks of treatment achieved full relief of depressive symptoms.  Additional data from the study will be forthcoming later this spring.

The purpose of the pilot study is to provide information necessary to help design a subsequent statistically significant randomized placebo controlled multi-center pivotal study. 

DepressiStim is the first and only non-invasive bioelectric stimulation device for depression that is designed to control expressions of specific proteins known to help in depression recovery, such as serotonin, BDNF and klotho.

Reference #1:  Lower klotho levels are associated with higher risk of depression https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548667/

Reference #2;  Klotho hold key to reducing negative stress effects on health https://www.drlamcoaching.com/blog/klotho-may-hold-the-key-to-reducing-negative-stress-effects-on-health/

Key facts

  • Depression is a common mental disorder. Globally, it is estimated that 5% of adults suffer from depression.
  • Depression is a leading cause of disability worldwide and is a major contributor to the overall global burden of disease.
  • More women are affected by depression than men.
  • Depression can lead to suicide.
  • There is a need for another alternative treatment for people that do not respond to drugs or have a bad side effect from drugs. 

This study is being supported by Leonhardt’s Launchpads Brazil located in Porto Alegre, Brazil with Dr. Cristiane Carboni as Research Coordinator.  DepressiStim is also being supported in part by the University of California Irvine (UCI) Capstone Program in the Engineering School with students and faculty assigned to help develop and test the generation two Brain Band TM design. 

Simultaneously to the ongoing clinical research and product's development, new pre-clinical studies are being initiated at Leonhardt's Launchpads R&D Lab in Irvine, California and the California Medical Innovations Institute/AcuLab in San Diego County.  These studies are designed to look at the safety, help gauge duration and dosing of stimulations, and discover new potential bioelectric signaling sequences and their corresponding protein expressions.  

About DepressiStim:  Founded in November 2015 DepressiStim is a spin out of the startup CerebraCell LTP www.cerebracell.com that is the Leonhardt’s Launchpads incubator and Cal-X Stars Business Accelerator, Inc. www.calxstars.com and www.calxelerator.com accelerator programs which includes mentorship services. This program includes shared access to R&D wet lab and prototyping space at University Lab Partners and UCI Cove in Irvine, California just off the campus of the University of California Irvine. The team focuses on applying precise control of selected circulating protein expressions via proprietary bioelectric signaling sequences.  See web site www.depressistim.com for more information. 

About Leonhardt Ventures LLC:  Founded in 1982 Leonhardt Ventures LLC has been a leader in developing breakthrough medical device innovation for over 4 decades.  See www.leonhardtventures.com   Leonhardt Ventures LLC has multiple hundreds of patent claims covering bioelectric, biologics and endovascular healing technologies - https://patents.justia.com/inventor/howard-j-leonhardt

Disclaimer:  Forward looking statements may change.  Please refer to risk factors in our private placement memorandum, annual report and on our web sites.  Patents pending may not be issued.  Patents issued may be invalidated. Early data may not translate to statistically significant data proving safety or efficacy.  Additional studies are needed to prove safety and efficacy. 

Media Contacts:

Company Name: DepressiStim LTP a Leonhardt Ventures LLC company
Full Name: Howard Leonhardt
Phone: 424- 291-2133
Email Address: Send Email
Website: http://www.depressistim.com

For the original news story, please visit https://www.prdistribution.com/news/depressistim-announces-clinical-trial-progress/9570167.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.